Long-Acting Injectable ART Superior to Standard Care for Poorly Adherent People With HIV
By Elana Gotkine HealthDay Reporter
TUESDAY, March 12, 2024 -- For people with HIV (PWH) and a history of suboptimal adherence to antiretroviral therapy, long-acting injectable treatment with cabotegravir and rilpivirine (LAI) is superior to oral standard of care (SOC), according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 3 to 6 in Denver.
Aadia I. Rana, M.D., from the University of Alabama at Birmingham, and colleagues compared LAI to oral SOC antiretroviral treatment in PWH with a history of suboptimal adherence. A total of 434 participants were enrolled to step 1 where they received conditional cash incentives for viral suppression on SOC of up to 24 weeks; 294 participants were then randomly assigned to monthly LAI versus continuation of SOC for 52 weeks (146 and 148 individuals, respectively).
The researchers found the two arms had similar cumulative probability of adverse events. Three participants receiving LAI had grade ≥3 injection site reactions (ISR), and one discontinued treatment due to ISR. The LAI arm was favored in all efficacy end points. The primary composite end point was the earliest occurrence of virologic failure or treatment discontinuation; for this interim analysis, the primary end point did not meet the predefined stopping criterion, but key secondary end points of virological failure and treatment-related failure met this criterion, indicating superiority of the LAI arm.
"This study shows long-acting technology is safe and effective among the people with HIV who stand to benefit most from its use," Rana said in a statement. "Offering an effective alternative for people who have struggled with taking daily ART could provide life-changing freedom from the stress of unsuppressed HIV."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Recommendations Developed for People With HIV Wanting to Breastfeed
MONDAY, May 20, 2024 -- In an American Academy of Pediatrics clinical report published online May 20 in Pediatrics, recommendations are presented for breastfeeding among people...
Cognitive Impairment Still Seen in Children, Teens With HIV
TUESDAY, April 30, 2024 -- Cognitive impairment persists in children and adolescents living with HIV even in the era of antiretroviral therapy (ART), according to research...
Pandemic Reignited Debate Regarding Physician's Obligation to Treat
MONDAY, April 29, 2024 -- There was a surge in ethics literature during COVID-19 advocating for the ethical acceptability of physicians refusing to treat, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.